Appeals court sets a September date in Lilly's fight with the FDA over retatrutide's drug class

The Seventh Circuit Court of Appeals has scheduled oral arguments for September 24, 2026, in Eli Lilly's appeal against the Food and Drug Administration over how retatrutide should be classified.^[1] The dispute centers on whether the experimental triple-agonist drug is a protein or a biological product. The answer decides how Lilly can file the drug with regulators and how long it would be protected from copycat competition once approved.^[1]

The FDA determined that retatrutide is neither a protein nor a biological product.^[1] A district court later vacated that determination but sent the broader question back to the agency rather than resolving it outright. Lilly appealed that outcome, which is what brought the case to the Seventh Circuit.^[1] Lilly has said it intends to file retatrutide as a Biologics License Application rather than a New Drug Application, but the company has acknowledged that classification remains subject to the unresolved litigation.^[1]

The stakes are concrete. A Biologics License Application carries twelve years of market exclusivity. A New Drug Application carries five.^[1] Lilly has told investors it plans to submit retatrutide to the FDA in the first quarter of 2027.^[1] The company said on August 5, 2026, that the clinical data package supporting that filing is now complete, following positive results from two Phase 3 trials, TRIUMPH-2 and TRIUMPH-3, reported on July 23, 2026.^[1] In TRIUMPH-3, adults with severe obesity and established cardiovascular disease lost up to 22.6% of body weight at 80 weeks. In TRIUMPH-2, participants with type 2 diabetes lost up to 20.8% of body weight over the same period.^[1] The data package is meant to support applications in obesity, obstructive sleep apnea, and knee osteoarthritis pain.^[1]

Why it matters for patients

Retatrutide is not approved anywhere and is not legally available in the United States. It is still investigational, which is why Lilly has filed six US lawsuits this year against sellers offering unapproved versions of the drug.^[1] For patients, that means any retatrutide currently being sold outside a clinical trial has not gone through FDA review for safety or effectiveness.

The exclusivity question matters mostly for what comes later. If the drug is eventually approved as a biological product, it would be protected from biosimilar competition for twelve years. If it is approved as a conventional drug, generic-style competitors could potentially enter after five years.^[1] A longer exclusivity period generally means a longer stretch before lower-cost competitors can enter the market, though pricing and insurance coverage depend on many other factors not addressed in this case. The court's ruling will not change whether retatrutide gets approved. It will only settle which regulatory pathway applies and how long that exclusivity clock runs once approval happens.

What happens next

Oral arguments are set for September 24, 2026, at the Seventh Circuit.^[1] Separately, Lilly has said it plans to submit retatrutide to the FDA in the first quarter of 2027, though the filing type may still depend on how the appeal resolves.^[1] No FDA approval decision or exclusivity determination has been made yet, and the timing of a ruling from the appeals court is not stated in company or regulatory disclosures reviewed here.^[1]